September 27, 2024
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Tyler Howes and Tim Buchmiller
| Re: |
Cartesian Therapeutics, Inc.
Registration Statement on Form S-1 (the “Registration Statement”) File No. 333-281204 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cartesian Therapeutics, Inc. (the “Company”) hereby respectfully
requests that the effective date of the above-referenced Registration Statement be accelerated to 4:00 p.m., Eastern Time, on October 1, 2024, or as
soon as practicable thereafter.
Please contact Sarah C. Griffiths of Covington & Burling LLP at (617) 603-8815 or sgriffiths@cov.com with any questions you may have
regarding this request. In addition, please notify Ms. Griffiths by telephone when this request for acceleration has been granted.
|
Very truly yours,
|
||
|
CARTESIAN THERAPEUTICS, INC.
|
||
|
By:
|
/s/ Carsten Brunn
|
|
|
Name:
|
Carsten Brunn
|
|
|
Title:
|
President and Chief Executive Officer
|
|
| cc: |
Brian K. Rosenzweig, Covington & Burling LLP
Sarah C. Griffiths, Covington & Burling LLP |